British Journal of Dermatology
British Journal of Dermatology
5 years ago

Intravenous Immunoglobulin as Adjunct Therapy for Refractory Pyoderma Gangrenosum: Systematic Review of Cases and Case Series

N. Lahood, H. Song, A. Mostaghimi
Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis. Treatment regimens for refractory cases are non-standardized. Intravenous immunoglobulin (IVIG) is an emerging treatment with reported success, but the efficacy of IVIG for PG is unknown. In this systematic review of cases and case series, we assessed the efficacy of IVIG for treatment of PG, as observed at our institution and reported in the literature. A retrospective chart review at two tertiary care hospitals between 2000-2015, and literature searches in PubMed/MEDLINE, EMBASE, and Web of Science from all years were conducted. There were 49 total patients, including 43 patients from 26 articles and 6 institutional cases. There was complete or partial response in 43 (87.8%) patients and complete response in 26 (53.1%) patients. The mean time to initial response to treatment and treatment length were 3.5 (3.3) weeks and 5.9 (7.8) months, respectively. On average, 2.6 treatments had been trialed before IVIG initiation. IVIG was administered with systemic steroids in 43 (87.8%) cases. Mild adverse events, especially nausea and headache, were reported in 12 (24.5%) patients. Our systematic review suggests a potential role for IVIG as adjuvant therapy for refractory PG. Prospective clinical trials testing the efficacy of IVIG for refractory PG are needed to validate these findings. This article is protected by copyright. All rights reserved.

Publisher URL: http://onlinelibrary.wiley.com/resolve/doi

DOI: 10.1111/bjd.15850

You might also like
Discover & Discuss Important Research

Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.